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Abstract. Beside its role as a neurotransmitter in the
central nervous system, serotonin appears to be a
central physiologic mediator of many gastrointestinal
(GI) functions and a mediator of the brain-gut
connection. By acting directly and via modulation of
the enteric nervous system, serotonin has numerous
effects on the GI tract. The main gut disturbances in
which serotonin is involved are acute chemotherapy-
induced nausea and vomiting, carcinoid syndrome and
irritable bowel syndrome. Serotonin also has mito-
genic properties. Platelet-derived serotonin is in-
volved in liver regeneration after partial hepatectomy.
In diseased liver, serotonin may play a crucial role in
the progression of hepatic fibrosis and the patho-
genesis of steatohepatitis. Better understanding of the
role of the serotonin receptor subtypes and serotonin
mechanisms of action in the liver and gut may open
new therapeutic strategies in hepato-gastrointestinal
diseases.
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Serotonin (5-hydroxytryptamine, 5HT) has been the
subject of intense biological research since its syn-
thesis in 1951 [1]. Erspamer and Asero [2] originally
isolated a potent vasoconstrictor substance from the
intestine, which they called enteramine. In 1948,
Rapport and colleagues determined that this new
substance was chemically 5-hydroxytryptamine, and
named it serotonin [3]. Serotonin was subsequently
found in the gastrointestinal (GI) tract and central
nervous system (CNS) and shown to function both as a
neurotransmitter and as a local hormone in the
peripheral vascular system and in the gut [4–6].
With increasing knowledge, serotoninwas shown to be
amediator with a subsidiary role inmany functions. In
words of one pundit, serotonin seemed to be involved
in everything, but responsible for nothing, a kind of
mediator-without-portfolio.
Novel agonists and antagonists of serotonin led to the
identification of several types and subtypes of
receptors, which are currently at the forefront of
pharmacologic research in neuroscience and gastro-
enterology [7]. GI research on serotonin was initially
stimulated by the observation of high amounts of
serotonin in the intestinal mucosa [8]. The role of
serotonin was further elaborated by the study of
carcinoid tumors [9] and that mucosal application of
serotonin activates afferent nerve endings causing
intestinal peristalsis [10]. Over the past 20 years,
serotonin has gained recognition well beyond its role
as a neurotransmitter in the CNS. It appears as a
physiologic mediator of GI function and motility and
a component of pathological conditions. It even
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appears as a mediator of the brain-gut connection
[11].
Serotonin also has mitogenic properties [12, 13], for
example in modulating growth of a variety of tissues
like smooth muscle cells and fibroblasts in pulmonary
hypertension, the nervous system [14] and the mam-
mary gland [15]. The development of knock-out mice
lacking peripheral serotonin opened new avenues for
specific research approaches looking at the effects of
serotonin outside the nervous system [16]. The liver
was one of the organs that benefited much from these
genetic tools, since serotonin has been shown to play a
pivotal role in liver regeneration aftermajor tissue loss
following hepatectomy [17] and tissue repair after an
ischemic insult [18]. Serotonin was also found to
mediate injury in the highly prevalent liver disease,
steatohepatitis [19].
The goal of this review is to provide an overview of the
implications of serotonin in the hepato-GI tract. We
will focus onGImobility, liver regeneration, ischemia/
reperfusion (I/R) injury and chronic liver disease, as
well as pancreas regeneration. Clinical implications
and perspectives of strategies modulating the activity
of serotonin, 60 years after its characterization, will be
discussed.
What is serotonin?
The phylogenetically old molecule serotonin [3-(2-
aminoethyl)-5-hydroxyindole] is widely distributed in
animals, fungi and plants, including fruits and vegeta-
bles.
Serotonin synthesis and metabolism
About 95% of serotonin in the body is found in theGI
tract, of which 90% is in enterochromaffin cells (ECs)
and 10% in enteric neurons. The remaining of
serotonin (5%) is found in the brain. As serotonin
cannot cross the blood-brain barrier, the brain must
synthesize its own serotonin. Virtually all of the
serotonin in the blood is derived from the GI tract
[20, 21]. Serotonin is present and synthesized in
enteric nerves [22–25]. Serotonin is present at high
concentration in platelets, where it accumulates from
the plasma by an active transport system and partic-
ipates in aggregation of platelets and coagulation of
blood [20, 21]. Though serotonin is present in the diet,
most of it is metabolized before entering the blood-
stream. In ECs and neurons, but not in platelets,
serotonin is synthesized from the essential amino acid
tryptophan by two enzymatic steps. First, hydroxyla-
tion of tryptophan by the enzyme tryptophan hydrox-
ylase (TPH) (the rate-limiting step) produces 5
hydroxytryptophan (5-HTP). The second enzymatic
step is decarboxylation of 5-HTP by the enzyme L-
aromatic amino acid decarboxylase producing sero-
tonin [26] (Fig. 1). Platelets (and neurons) possess a
high-affinity serotonin uptake mechanism, and plate-
lets become loaded with serotonin as they pass
through the intestinal circulation, where the local
concentration is relatively high. Therefore, about 95%
of serotonin found in blood is stored in platelets [27].
Serotonin in tissues can be very rapidly metabolized,
mainly as a result of the activity of monoamine
oxidase. In the kidney and the liver, the enzymes
monoamine oxidase and aldehyde dehydrogenase
convert serotonin to 5-hydroxyindole acetic acid (5-
HIAA), which is excreted in the urine.
Figure 1. Biosynthesis of seroto-
nin.
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The gut, as well as the CNS, has an inactivating
mechanism, a transporter-mediated uptake (serotonin
reuptake transporter, SERT), which is present both in
the mucosa and in nerves of the enteric nervous
system [28, 29]. This system plays an important role in
terminating transmitter action and in maintaining
transmitter homeostasis because there is no extrac-
ellular enzyme, analogous to acetylcholinesterase,
that rapidly catabolizes serotonin. Mice that lack
SERTexhibit increased colonicmotility and increased
water in stools and display an alternating pattern of
diarrhea and constipation.
There are two isoforms of TPH [16]. TPH1 is present
in the periphery, especially in the duodenum, while
TPH2 is present exclusively in the brain and is
encoded by a different gene [30]. Therefore, it was
possible to generate mice genetically deficient for
TPH1 (TPH/), which lack serotonin in the periph-
ery and exhibit no significant behavioral differences
with their wild-type siblings [16]. Finally, it is possible
to increase serotonin formation by administrating 5-
HTP. Because decarboxylase is ubiquitous in mam-
malian cells, these mice are able to produce serotonin
everywhere after administration of the serotonin
precursor 5-HTP, bypassing the rate-limiting TPH
step [17]. The development of such knock-out mice
has allowed the performance of in vivo experiments
highlighting novel effects of serotonin in the periph-
ery.
Serotonin receptor classification
Serotonin receptors are present in enteric neurons,
ECs, GI smooth muscle cells and possibly in enter-
ocytes, immune tissues and hepatocytes [31, 32].
Seven types or families and multiple subtypes of
serotonin receptors have now been identified by a
combination of pharmacological techniques and
molecular cloning [33]. The seven recognized types
or families of serotonin receptors are termed 5-HT1
through 5-HT7. Information concerning the types
and subtypes of serotonin receptors is summarized in
Table 1, with a focus on GI effects. Subtypes of the 5-
HT1 receptor are well characterized; these are
termed 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-
HT1P [7]. Originally, there was an 5-HT1C receptor,
but later it was found to be the 5-HT2C receptor and
thus this subtype was moved from the 5-HT1 family
to the 5-HT2 family. 5-HT1 and 5-HT2 receptorsmay
not be critically involved in the endogenous control
of gut motility [11]. Neuronal 5-HT3 receptors seem
Table 1. Classification of serotoninergic receptor subtypes with a focus on GI effects [adapted from refs 11 and 33].
Location GI effect
GI tract brain
5-HT1A enteric nerves hippocampus neuronal inhibition
5-HT1B sympathetic nerves substantia nigra,
basal ganglia
neuronal inhibition
5-HT1D substantia nigra,
basal ganglia
neuronal inhibition
5-HT1E substantia nigra,
basal ganglia
?
5-HT1F dorsal raphe,
hippocampus,
cortex
?
5-HT1P enteric nerves neuronal depolarization
5-HT2A ileum cortex,
caudate nucleus
contract muscle,
neuronal depolarization
5-HT2B stomach cerebellum ?
5-HT2C choroid plexus ?
5-HT3 vagus,
sympathetic,
enteric nerves
area postrema neuronal depolarization
5-HT4 myenteric plexus hippocampus contract muscle,
facilitate cholinergic transmission
5-HT5 cerebellum or whole brain
5-HT6 caudate nucleus
5-HT7 thalamus,
hypothalamus,
hippocampus
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to be the primary serotonin receptors responsible for
rapid depolarization responses inmyenteric neurons,
leading to increased release of acetylcholine from
cholinergic neurons, resulting in smooth muscle
contraction [11]. In the CNS, the highest levels of
5-HT3 receptors are in the brainstem, particularly in
the nucleus tractus solitaris, area postrema and
dorsal motor nucleus of the vagus nerve. These
structures are intimately involved in initiation and
coordination of the vomiting reflex; antagonism of
the 5-HT3 receptors in these nuclei is therefore likely
to contribute to the antiemetic action of 5-HT3
receptor antagonists such as ondansetron, granise-
tron and tropisetron. Peripherally, 5-HT3 receptors
are also located on vagal afferents and are important
(and, in some cases, additive to 5-HT4 effects) in the
peristaltic reflex [34–36]. Intestinal primary afferent
neurons have 5-HT4 receptors [37, 38]. 5-HT4
receptors are involved in the peristaltic reflex [34,
36]. The last three receptors (5-HT5, 5-HT6 and 5-
HT7) have been recently cloned and are distributed
predominantly in the brain [33].
Role of serotonin in the GI tract
Motor and sensory effects of serotonin in the gut
The bowel has the unique ability to mediate reflexes
independently from the brain and spinal cord [39].
The local nervous mechanism of the bowel, in which
serotonin is involved, is now known as the enteric
nervous system. The name was given by Langley in his
classic definition of the autonomic nervous system
[40]. Langley included the enteric nervous system as
one of three basic subdivisions of the autonomic
nervous system beside the sympathetic and para-
sympathetic nervous systems. There are strong inter-
actions between the enteric and central nervous
system.
In the enteric nervous system, serotonin acts as an
enteric neurotransmitter and a paracrine signaling
molecule [4–6]. In the gut, serotonin is released from
ECs acting locally in a paracrine fashion [41]. It has
diverse motor and sensory functions in the GI tract
through submucosal and myenteric neurons that
respond to serotonin through a variety of receptors.
Serotonin is involved in so many functions in the
bowel that it is difficult to determine which of these
actions are physiologically relevant. The multiplicity
of responses to serotonin can be attributed to the
expression within the gut wall of a wide variety of
serotonin receptor subtypes [5]. Serotonin initiates
diverse responses such as nausea, vomiting, intestinal
secretion and peristalsis, and plays a role in bowel
physiology as an enteric neurotransmitter. In phys-
iological studies of gut smooth muscle, serotonin
induces contraction or relaxation of the bowel,
depending on the experimental conditions [5, 11].
For example, serotonin activates both intrinsic ex-
citatory and inhibitory enteric motor neurons. It can
stimulate cholinergic neurons to release acetylcho-
line, which results in smooth muscle contraction, or it
can stimulate inhibitory nitrergic neurons to release
nitric oxide, which results in smooth muscle relaxa-
tion. Serotonin also participates in a vagal pathway
leading to relaxation of the stomach [11].
When intraluminal pressure increases, ECs release
serotonin, which stimulates vagal and intrinsic (en-
teric) afferent nerve fibers, initiating the peristaltic
reflex [10] (Fig. 2). In addition, serotonin appears to
be a signaling molecule, participating in mucosal
sensory transduction [39]. Serotonin also plays a role
in the descending pathways from the brainstem that
modulate afferent information processed by the
dorsal horn.
Themain determinant of gastric mechanosensitivity is
gastric tone. A subset of patients with functional
dyspepsia have been shown to have insufficient
accommodation (decrease in gastric tone) after a
meal [42, 43]. Pretreatment with the selective seroto-
nin reuptake inhibitor (SSRI) paroxetine has been
shown to enhance gastric accommodation to a meal in
healthy volunteers in the absence of any effect on
fasting gastric compliance [44]. These observations
suggest that serotonin release is involved in the
control of the accommodation reflex and therefore
in the modulation of visceral sensation during the
postprandial state. Prokinetic benzamides, such as
cisapride, act as 5-HT4 receptor agonists. Their
gastrokinetic properties are thought to originate
from their ability to stimulate 5-HT4 receptors on
cholinergic nerve terminals [45, 46]. The effect of
serotonin in a subset of myenteric neurons is known to
evoke a slow depolarizing response. This effect is
mediated by the so-called 5-HT1P receptors which are
predominantly located on inhibitory motor neurons of
the gastric myenteric plexus [47, 48]. Recent studies
have identified sumatriptan as a 5-HT1P receptor
agonist which interacts with nitrergic myenteric neu-
rons in the guinea pig stomach and which induces
gastric relaxation in cats and humans [49]. The non-
selective 5-HT1Areceptor agonist buspirone is thought
to decrease gastric tone and increase the distension-
induced volume thresholds in healthy volunteers,
thereby mimicking some of the effects of sumatriptan
[50]. In a placebo-controlled, double-blind, random-
ized, cross-over study, buspirone was shown to be
superior to placebo at improving gastric accommoda-
tion in patients with functional dyspepsia [51]. The 5-
HT1P and 5-HT1A receptor agonists may have addi-
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tional therapeutic potential for the treatment of gastric
visceral hypersensitivity.
Role in secretion control
Serotonin is also a potent intestinal stimulus for
secretion. The mechanisms of serotonin-induced in-
testinal secretion are unclear. A 5-HT2 receptor,
located in the mucosa, is involved in the regulation of
serotonin-stimulated intestinal electrolyte transport
[52]. Serotonin is involved in cholera toxin- and bile
salt-induced fluid and electrolyte secretion by activat-
ing the enteric nervous system, or, at least in part, via a
release of serotonin from ECs [53]. Serotonin is also
important in the pathophysiology of carcinoid diar-
rhea. Serotonin induces intestinal secretion, and
studies performed in a few patients with carcinoid
diarrhea using 5-HT3 antagonists demonstrated en-
hanced jejunal absorption in fluid transport [54].
Serotonin in GI disease
The main gut disturbances in which serotonin is
involved are acute chemotherapy-induced nausea
and vomiting, carcinoid syndrome and irritable
bowel syndrome (IBS).
Chemotherapy-induced nausea and vomiting. Sero-
tonin is a key mediator of chemotherapy-induced
nausea and vomiting. Several cancer chemotherapy
agents, like cisplatin, oxaliplatin or streptozotocin
induce the release of serotonin from ECs in the
duodenum. Released serotonin induces nausea and
vomiting through stimulation of 5-HT3 receptors on
vagal afferent nerves that convey information to the
medullary vomiting system including the area post-
rema [55]. Antagonists at 5-HT3 receptors have
proved to be highly effective antiemetic drugs. The
5-HT3 antagonist drugs most widely used and studied
to date are ondansetron, granisetron and tropisetron.
Their main use in clinical therapeutics is in the control
of cisplatin and other cytotoxic chemotherapy and
radiotherapy-induced emesis. 5-HT3 antagonists are
significantly more efficient than metoclopramide
during the first day after cisplatin treatment [56].
Carcinoid syndrome. There are convincing data
indicating that serotonin is responsible for the diar-
rhea associatedwith carcinoid tumors. Themajority of
carcinoid patients have raised levels of plasma sero-
tonin or urinary levels of its metabolite (5-HIAA),
and carcinoid tumors contain vast quantities of
serotonin [54]. Carcinoid diarrhea is caused by
increased jejunal secretion and alterations in small
bowel and colonic motor functions. Transit times in
the small bowel and colon in patients with carcinoid
diarrhea were, respectively, two and six times faster
than in healthy controls [54].
Drugs that block serotonin receptors, such as methy-
sergide and ketanserin, or that inhibit serotonin
synthesis, such as p-chlorophenylalanine, are effective
in the short-term treatment of diarrhea in this
population [11]. Ondansetron proved effective in
inhibiting carcinoid diarrhea and flushing [57, 58].
Figure 2. Action of serotonin in
the bowel wall. Serotonin re-
leased from stimulated entero-
chromaffin cells activates sub-
mucosal intrinsic primary effer-
ent neurons (pink) throught 5-
HT1P receptors. The latter
spread information to the myen-
teric plexus (blue) allowing peri-
staltic reflexes. Serotonin also
activates extrinsic sensory neu-
rons (purple) which relay infor-
mation to the central nervous
system. Black arrows represent
reuptake of selective serotonin
by its transporter (SERT) which
is blocked by serotonin reuptake
inhibitor (SSRI).
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Irritable bowel syndrome. IBS is associated in some
patients with altered GI transit, a variety of mano-
metric abnormalities in the small and large intestine,
increased visceral sensation and psychological fea-
tures including depression and anxiety. IBS can be
subdivided into diarrhea-predominant, constipation-
predominant ormixed IBS [59, 60]. GI symptomsmay
result from dysregulation of the brain-gut mediation
[61]. Although changes in the metabolism and/or
function of serotonin have been well documented in
patients with IBS, further work is needed to clarify the
role of serotonin and its transporter in the syndrome.
For example, patients with diarrhea-predominant IBS
have higher levels of plasma 5-HT under both fasted
and fed conditions than healthy controls, whereas
patients with constipation-predominant IBS show
little or no changes in plasma serotonin levels after
meals [59, 62]. It has been suggested that increased
levels of 5-HTmight exert prokinetic effects in the GI
tract, leading to diarrhea, whereas the reduced levels
of serotonin in constipation-predominant IBS may
cause constipation.
Although the exact role of serotonin in IBS is not
clear, selective 5-HT3 antagonists, such as ondanse-
tron, granisetron or alosetron, appear to be promising
therapeutic drugs for IBS. The potential modes of
action of 5-HT3 antagonists could include decrease of
visceral nociception [63], inhibition of the gastro-
colonic reflex [64], inhibition of colonic mobility and
compliance, inhibition of small bowel transit [65] and
beneficial central effects on anxiety [66]. Several
placebo-controlled studies have suggested benefits of
5-HT3 receptor antagonists in patients with IBS [6].
5-HT4 receptor agonists, e.g. tegaserod, stimulate
motility and secretion through enhanced release of
acetylcholine from excitatory motor neurons and
interneurons. Several studies established that treat-
ment with tegaserod for up to 12 weeks is able to
improve constipation and to provide relief of pain/
discomfort and bloating in constipation-predominant
IBS [67]. 5-HT4 receptor agonists exert modest but
inconsistent effects on esophageal motility and on
gastroesophageal reflux in patients with gastroeso-
phageal reflux disease [68]. 5-HT4 agonists do not
compare well with the gold standard of therapy for
gastroesophageal refluxwith a proton pump inhibitor;
a place for 5-HT4 agonists in the management of
gastroesophageal reflux has therefore not been estab-
lished. Finally, 5-HT4 receptor agonists might be
efficient in gastroparesis [69].
Colorectal cancer. Thirty years ago, a proliferative
effect of serotonin in a xenograft mouse model of
colorectal cancer was reported. SSRIs significantly
suppressed tumor growth in this model [70–73]. The
data appear quite relevant as SSRIs are frequently
used as antidepressants.
Newer studies using electron microscopy immuno-
chemistry proposed serotonin as a carcinogenic sub-
stance in colon cancer differentiation [74]. Further-
more, a decreased metabolic activity and growth of
cultured human colorectal carcinoma after treatment
with SSRIs was reported [75]. Recently, a large
epidemiological study described a reduced risk of
colorectal cancer after daily intake of SSRIs com-
paredwith non-users of such antidepressants [76]. The
biological mechanisms of these findings remain un-
known and need further investigation [76].
Role of serotonin in the liver
Role of platelets
Platelets play a key role in haemostasis and thrombo-
sis [77]. Platelets are also involved in the inflamma-
tory reaction after many types of tissue injury,
independent of coagulation [78]. In the liver, platelets
interact with leukocytes in response to cold ischemia,
enhancing leukocyte adhesion to the endothelium,
thereby causing tissue injury [79, 80]. Concurrent
activation of liver macrophages, called Kupffer cells,
leads to further endothelial cell damage and hepato-
cyte apoptosis and necrosis [81].
Our group investigated the role of platelets in liver
regeneration using a model of 70% hepatectomy in
mice rendered thrombocytopenic, or those with
pharmacologically impaired platelet activity [17]. In
bothmodels, the regenerative capacity of the liver was
impaired, suggesting that platelets play an important
role in liver regeneration. In a previous study on
hepatic regeneration in rats, it was noted that splenec-
tomized rats with increased platelet counts had
improved liver regeneration via an unclear mecha-
nism involving a growth factor [82]. Murata et al. [83]
recently examined the effect of platelet increment on
liver regeneration. Hepatectomies were carried out in
untreated mice, thrombocytotic mice induced with
thrombopoietin, and thrombocytopenic mice induced
by antiplatelet antibody. The researchers showed that
in thrombocytotic and thrombocytopenic mice, mark-
ers of liver regeneration were, respectively, increased
and decreased, when compared with untreated mice.
They also demonstrated that platelets accumulated in
the residual liver in the early period after hepatec-
tomy.
Role of serotonin in liver regeneration
Platelets contain many growth factors, such as plate-
let-derived growth factor (PDGF), hepatocyte growth
factor, epidermal growth factor (EGF) and vascular
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endothelial growth factor in the a granules [77]. In
their dense bodies, they also store and release
serotonin, which acts as a growth factor [12, 13]. In
vitro, serotonin is a potent mitogen and stimulates
mitosis of smooth muscle cells [13]. The role of
serotonin in liver regeneration in hepatocyte cell
cultures has been reported, with serotonin causing a
dose-dependent increase in (3H)-thymidine incorpo-
ration into hepatic DNA in the presence of insulin and
EGF [84]. The 5-HT2A and 2C receptors appear to
mediate mitogenic effects in fibroblasts [85, 86], and
the 5-HT2B receptor is involved in the development
of the heart [87] and the enteric nervous system [88].
Furthermore, in transfected fibroblasts and renal
mesangial cells, a mitogenic cross-talk of serotonin
receptors 5-HT2A and 5-HT2B has been shown with
EGF receptor and PDGF receptor, respectively [89,
90]. Very recently an additional cross-talk of SERT
and PDGFb receptor in smooth muscle cells has been
described, which leads to proliferation and migration
[91].
With the exception of a mention in the Russian
radiobiology literature about 20 years ago [92, 93], the
effect of serotonin on hepatic regeneration was
unknown. We recently showed that platelet-derived
serotonin is involved in liver regeneration [17]. In
thrombocytopenic mice, a serotonin agonist restored
the deficient hepatic proliferation. The mRNA ex-
pression of serotonin receptor subtypes 5-HT2A and
2B increased after partial hepatectomy, and antago-
nists of these receptors inhibited liver regeneration.
Furthermore, knock out mice TPH/, lacking
peripheral serotonin due to an absence of the rate-
limiting synthetic enzyme TPH1, exhibited an im-
paired liver regeneration after partial hepatectomy.
This failure of regeneration was rescued by reloading
serotonin-free platelets with the injection of the
serotonin precursor 5-HTP. Papadimas et al. [94]
investigated the effect of 5-HT2 blockage by ketan-
serin on liver regeneration after partial hepatectomy
in rats. Administration of ketanserin can arrest liver
regeneration onlywhen administrated close to theG1/
S transition point, which suggests that serotonin may
be a cofactor for DNA synthesis.
Serotonin could also play a role in liver regeneration
at the cerebral level. The relationship between the
functional status of the liver and the brain has been
known for centuries. In hepatic encephalopathy and
other liver diseases, neurotransmission in the brain is
reported to be altered [95, 96]. The serotonin brain
circuits are known to be involved in hepatic encephal-
opathy [97]. Lateral lesions of the hypothalamus cause
an increase in DNA synthesis during liver regener-
ation, while sympathectomy and vagotomy block this
effect [98]. More recently, Pyroja et al. [99] showed
that the brain 5-HT2C receptor was up-regulated
during liver regeneration after partial hepatectomy
and in hepatic neoplasia. The increased serotonin
content and 5-HT2C receptor in the brainstem and
cerebral cortex is suggested to facilitate the active
hepatocyte proliferation, possibly through the sym-
pathetic stimulation [99].
Role of serotonin in hepatic I/R injury
While inhibition of platelet activity reduces ischemic
tissue injury in the heart [100], lung [101] and pancreas
[102], little is known about the impact of platelets and
serotonin on normothermic I/R injury of the liver.
Mice deficient for P-selectin, an adhesion molecule
critical to the postischemic platelet-endothelial cell
interaction [103], display reduced platelet and neu-
trophil sequestration and a better survival following
warm ischemia [104]. In addition, the inhibition of
platelet adhesion by the administration of antifibri-
nogen antibody decreases short-term liver injury after
ischemia [105]. However, these experimental ap-
proaches also inhibit leukocyte-mediated effects;
thus, the specific contribution of platelets to warm I/
R injury of the liver remained unknown.
Murata et al. [106] investigated the role of serotonin
and platelet function in the pathogenesis of hepatic I/
R injury in a model of 60 and 90 min hepatic warm
ischemia in dogs using a portocaval shunt. Hepatic I/R
resulted in increased platelet aggregation and in-
creased serotonin levels in the hepatic veins, but not in
the portal vein. We recently assessed the role of
platelets in normothermic I/R injury in liver using
models of impaired platelet function, immune throm-
bocytopenia, and mice lacking TPH1 (TPH/) [18].
Neither inhibition of platelet function nor platelet
depletion led to a reduction of postischemic tissue
injury. Interestingly, postischemic inflammation, as
well as liver regeneration and consequently tissue
repair, were strikingly impaired. In particular, plate-
let-derived serotonin was found to mediate hepato-
cyte proliferation, which is an integral component of
postischemic tissue repair. Liver regeneration and
repair were significantly impaired in platelet-depleted
animals. Mice lacking peripheral serotonin were
deficient in hepatocyte proliferation, but otherwise
displayed normal tissue remodeling.The results acquit
platelets of causing postischemic liver injury, but
highlight their importance in different steps of pos-
tischemic tissue repair through the modulation of
inflammation and the release of serotonin.
Role of serotonin in non-alcoholic steatohepatitis
Very recently, our group suggested that serotonin
degradation plays a major role in the pathogenesis of
non-alcoholic steatohepatitis (NASH) [19]. NASH is
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thought to result froma two-hit process [107]. The first
hit is the hepatocellular accumulation of fatty acids,
which sensitizes the liver to further injury. Oxidative
stress acts as a second hit, leading to lipid peroxida-
tion, mitochondrial damage (megamitochondria),
hepatocellular injury (ballooning, Mallory bodies),
and finally to chronic inflammation and fibrosis.
Degradation of serotonin is catalyzed by the mito-
chondrial enzyme monoamine oxidase A, generating
5-HIAA as well as reactive oxygen species (ROS)
such as hydrogen peroxide. ROS generated by mono-
amine oxidase-mediated catabolism of serotonin were
recently reported to play a pivotal role in cardiomyo-
cyte death [108]. In a murine model of diet-induced
steatohepatitis, TPH/ mice displayed an equal
degree of steatosis, yet reduced hepatocellular injury
and less severe inflammation compared to wild-type
mice. The difference in these two NASH-defining
features was attributed to an increased uptake and
catabolism of serotonin, yielding enhanced levels of
ROS and lipid peroxides, which mediated hepatocel-
lular injury by mitochondrial damage and inflamma-
tion. This was the first study disclosing SERTexpres-
sion in the mouse liver, as well as in patients with
NASH and provides evidence that serotonin plays a
crucial role in the pathogenesis of steatohepatitis.
SERT might offer a novel target for the prevention
and treatment of NASH.
Serotonin in liver cirrhosis
Different studies have shown decreased concentra-
tions of intra-platelet serotonin in cirrhotic patients
[109–111]. Beaudry et al. [112] found higher plasma
levels of serotonin in patients with cirrhosis, whereas
levels of the serotonin metabolite 5-HIAA were
significantly decreased. They concluded that seroto-
nin metabolism was impaired in cirrhotic patients.
The hepatic stellate cell (HSC) is recognized as one of
the key mediators in the progression of hepatic
fibrosis [113, 114]. In normal healthy liver, HSC
function is to regulate sinusoidal blood and the traffic
of macromolecules across the space of Disse, and
HSCs also act as a store for vitamin A. Following
chronic injury, HSCs are involved in hepatic wound
healing and fibrosis. Serotonin was found to attenuate
apoptosis and to costimulate proliferation of HSCs in
the presence of PDGF in cultured rat HSCs [115].
Proliferation was inhibited and the apoptosis rate was
increased with 5-HT2B receptor antagonists. The
transcription of connective tissue growth factor was
increased in rat HSCs after incubation with serotonin.
5-HT2B receptor expression was associated with
fibrotic tissue in immunohistological stainings of rat
livers from a CCL4-cirrhosis model. Finally, HSCs
were shown to express a functional SERT and to
participate in both active uptake and release of
serotonin. The authors suggested that HSCs respond
to serotonin in a profibrogenicmanner and that 5-HT2
receptor antagonists may also be used for the treat-
ment of liver disease.
Recent reports have demonstrated the presence of
serotonin receptors in glomerular mesangial cells
[116, 117]. Furthermore serotonin has been reported
to stimulates the production of transforming growth
factor b (TGF-b) and type IV collagen in human
mesangial cells through the 5-HT2A receptor [117].
Since glomerular mesangial cells and HSCs are of
similar histological origin, the roles of glomerular
mesangial cells in glomerular disease resemble those
of HSCs in liver cirrhosis. Li et al. [118] demonstrated
that serotonin enhanced production of TGF-b by
HSCs through the 5-HT2A receptor and may play a
role in the pathogenesis of liver cirrhosis and portal
hypertension.
Serotonin in chronic cholestasis
Serotonin is involved in clinical symptoms of chol-
angiopathies like pruritus and fatigue [119]. In a rat
model of cholestasis, a selective 5-HT1A agonist
improved overall activity [120]. The authors specu-
lated that an enhancement of serotonergic neuro-
transmission mediated through 5-HT1A receptors
alleviates fatigue in cholestatic liver disease. A recent
study has shown the expression of the serotonin
receptors 1A and 1B in rat cholangiocytes [121]. Their
activationmarkedly inhibits the growth and choleretic
activity of the biliary tree. Cholangiocytes from
cholestatic rats overexpressed and oversecreted sero-
tonin, and treatment with a neutralizing antibody of
serotonin enhanced cholangiocyte proliferation. The
authors stressed the existence of an autocrine loop
based on serotonin that limits the growth and the
functional activity of the biliary tree in the course of
chronic cholestasis. These findings suggested the
involvement of serotonin-mediated pathways in cho-
lestatic disease. However, a recent randomized con-
trolled trial did not suggest any benefit of ondansetron
in the treatment of pruritus and scratching activity in
chronic cholestasis [122].
Serotonin in pancreatic regeneration
Pancreatic regeneration has been studied in small
animals and knowledge in this field is now expanding,
especially in the areas dealing with molecular biology
and genetic science [123]. However, knowledge of
pancreas regeneration in humans is limited to date.
Many transcription factors, such as PDX-1 and growth
factors, such as EGF or vascular endothelial growth
factor, have been suggested to be involved in the
proliferation, differentiation and maintenance of
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endocrine and exocrine pancreas. Unlike liver regen-
eration, there are no data showing a direct role of
serotonin in pancreas regeneration. However, recent
studies have suggested that hypothalamic serotonin,
through 5-HT1A and 5-HT2C receptors, has a func-
tional role in pancreatic regeneration via sympathetic
regulation [124–126]. These very early results would
suggest that the regeneration of the remnant pancreas
after subtotal pancreatectomy would be a good target
of certain therapies modulating serotonin action to
enhance pancreatic regeneration.
Conclusion and perspectives
Recent research advances have shown that many
effects of the well-known molecule serotonin remain
largely unknown
Serotonergic modulation of upper gut sensitivity
appears promising for the development of novel
approaches for the treatment of functional disorders
of the upper GI tract. However, it is apparent that the
mechanisms underlying the many effects on the GI
tract have yet to be fully elucidated. 5-HT3 antago-
nists are established treatment in patients with
diarrhea-predominant IBS and those with nausea-
associated chemotherapy. 5-HT4 agonists have bene-
ficial effects in patients with constipation-predomi-
nant IBS and chronic constipation. The role of 5-HT4
receptor agonists in functional dyspepsia, gastropa-
resis, gastroesophagial reflux and functional dyspepsia
is still under investigation.
Serotonin has been shown to be involved in several
liver diseases like I/R injury, steatohepatitis, chronic
cholestasis and liver cirrhosis. It may play an impor-
tant role in the progression of hepatic fibrosis through
HSCs [115]. However, it is unclear whether altered
serotonin homeostasis is a driving force in the
progression of hepatic fibrosis or is instead a conse-
quence of fibrosis. Nevertheless, these findings raise
the possibility that serotonin receptor antagonistsmay
have potential as future therapeutic agents in the
treatment of chronic liver disease like cirrhosis, which
remains a major public health problem worldwide.
There are now increasing arguments that serotonin
can act as a potent growth factor, for example in liver
regeneration. Since platelets carry the majority of
serotonin in the bloodstream, the relationship be-
tween platelets, serotonin and liver regeneration
could have direct ramifications for clinical care.
Platelet dysfunction and thrombocytopenia are com-
mon in cirrhotic patients undergoing liver transplan-
tation due to portal hypertension and subsequent
hypersplenism. Furthermore, during living-donor
liver transplantation, liver regeneration is crucial for
both the donor and the recipient patients [127, 128].
This is particularly critical in those recipients that
experience small-for-size liver graft dysfunction [129].
Another population inwhich thrombocytopenia could
potentially impair liver regeneration are those pa-
tients receiving neoadjuvant chemotherapy prior to
undergoing elective liver resection for malignancy.
Preoperative chemotherapeutic agents often cause
significant bone marrow suppression including rela-
tive thrombocytopenia.Modulating serotonin content
locally or increasing platelet counts systemically may
be an effective strategy to improve liver regeneration
and function in the transplant setting or following
major hepatic resection.
Further exploration of downstream effects of seroto-
nin in the hepatocyte cell cycle and its interaction with
other cytokines and growth factors will provide a
better understanding of the complex pathways in-
volved in liver regeneration [130]. Platelet-derived
serotonin may directly influence the proliferation of
hepatocytes [84] or may be involved in the release of
growth factors, such as interleukin-6 at the site of liver
injury [131, 132]. Greater knowledge of the role of the
serotonin receptor subtypes and the genes regulating
these mechanisms will be important in understanding
the biological basis and response to therapy (pharma-
cogenomics) in functional liver and GI disorders.
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